🫘 DIABETIC KIDNEY DISEASE: TREATMENT & KIDNEY PROTECTION
Treatment of diabetic kidney disease is no longer just about controlling blood sugar. Today we have several treatment classes that can address kidney, cardiovascular and metabolic risk together.
💊 ACE inhibitors -ARBs — such as Telmisartan, Losartan, Ramipril or Enalapril, particularly when hypertension and or albuminuria is present.
💧 SGLT2 inhibitors — such as Dapagliflozin and Empagliflozin, which have important kidney and cardiovascular benefits in appropriate people with type 2 diabetes and CKD.
💊 Finerenone — a non-steroidal MRA that can reduce kidney and cardiovascular risk in appropriately selected people with type 2 diabetes, CKD and albuminuria.
💉 GLP-1 receptor agonists — including Semaglutide, which can help with glucose and weight management and has demonstrated cardiovascular and kidney benefits.
💉 Tirzepatide (Mounjaro) — a dual GIP-GLP-1 medicine with strong glucose and weight-management effects and promising emerging kidney data.
❤️ And don’t forget the basics: BP control, healthy diet, less salt, physical activity, avoiding smoking and regular kidney monitoring remain essential.
The right combination depends on kidney function, albuminuria, potassium, blood pressure, diabetes control, cardiovascular risk, weight and other individual factors.
👉 Never start or stop these medicines without medical advice.
Detect early. Treat appropriately. Protect your kidneys.
#DiabeticKidneyDisease #DiabetesAndKidneys #KidneyHealth #CKD #KidneyCare #SGLT2Inhibitors #Dapagliflozin #Empagliflozin #Finerenone #Semaglutide #Tirzepatide #Mounjaro #ACEInhibitors #ARBs #Telmisartan #Nephrology #KidneyProtection #DiabetesCare
Treatment of diabetic kidney disease is no longer just about controlling blood sugar. Today we have several treatment classes that can address kidney, cardiovascular and metabolic risk together.
💊 ACE inhibitors -ARBs — such as Telmisartan, Losartan, Ramipril or Enalapril, particularly when hypertension and or albuminuria is present.
💧 SGLT2 inhibitors — such as Dapagliflozin and Empagliflozin, which have important kidney and cardiovascular benefits in appropriate people with type 2 diabetes and CKD.
💊 Finerenone — a non-steroidal MRA that can reduce kidney and cardiovascular risk in appropriately selected people with type 2 diabetes, CKD and albuminuria.
💉 GLP-1 receptor agonists — including Semaglutide, which can help with glucose and weight management and has demonstrated cardiovascular and kidney benefits.
💉 Tirzepatide (Mounjaro) — a dual GIP-GLP-1 medicine with strong glucose and weight-management effects and promising emerging kidney data.
❤️ And don’t forget the basics: BP control, healthy diet, less salt, physical activity, avoiding smoking and regular kidney monitoring remain essential.
The right combination depends on kidney function, albuminuria, potassium, blood pressure, diabetes control, cardiovascular risk, weight and other individual factors.
👉 Never start or stop these medicines without medical advice.
Detect early. Treat appropriately. Protect your kidneys.
#DiabeticKidneyDisease #DiabetesAndKidneys #KidneyHealth #CKD #KidneyCare #SGLT2Inhibitors #Dapagliflozin #Empagliflozin #Finerenone #Semaglutide #Tirzepatide #Mounjaro #ACEInhibitors #ARBs #Telmisartan #Nephrology #KidneyProtection #DiabetesCare
Keywords
